GBG
LightNews LightNews
banner
gbg.de
GBG
@gbg.de
100 followers 130 following 110 posts
Healing through innovation, competence and partnership. #BreastCancer #CancerResearch #ClinicalTrials
https://www.gbg.de/
Posts Replies Media Videos
gbg.de
🔍 #SABCS2025: #INSEMA Trial – #Radiotherapy Analysis (presented by Guido Hildebrandt)
Today’s presentation offered important insights into how radiotherapy was actually applied among patients undergoing breast-conserving surgery with or without sentinel lymph node biopsy #SLNB in the INSEMA trial.
December 11, 2025 at 10:15 PM
gbg.de
#SABCS2025 Update: #INSEMA – Secondary results presented by Toralf Reimer

INSEMA Rando2 adds robust data on the oncological #safety of omitting cALND in patients with positive SLNB, under conditions of strict regional nodal irradiation #RNI and #radiotherapy quality assurance.
December 11, 2025 at 8:07 PM
gbg.de
📣 Meet #GBG at #SABCS2025 – Highlights for December 11!

A full and inspiring third day at the SABCS brought important new insights into #axillary #surgery, #radiotherapy strategies, #translational #biomarkers, and international collaborations shaping the future of #breast #cancer care.
December 11, 2025 at 8:05 PM
gbg.de
At #SABCS2025, new translational results from the #NSABP B-59/GBG-96- #GeparDouze trial were presented by Carsten Denkert, highlighting how #TIL levels and molecular #TNBC subtypes shape response to #neoadjuvant immune-chemotherapy.

➡️ Full details are available here:
www.gbg.de/news/detail/...
December 11, 2025 at 7:50 PM
gbg.de
📢 Hot from the Press: Now published in #NEJM!

We are excited to share that the pivotal DESTINY-Breast05 data „Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer“ presented by Sibylle Loibl at #SABCS2025, is now available.
🔗 Read the full NEJM article:
www.nejm.org/doi/full/10....
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer | NEJM
Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer and residual disease after neoadjuvant therapy are at high risk for recurrence. In a phase 3, open-label, ...
www.nejm.org
December 10, 2025 at 10:14 PM
gbg.de
#SABCS2025: S. Loibl presented additional efficacy and safety data from the DESTINY-Breast05 trial, evaluating trastuzumab deruxtecan vs trastuzumab emtansine as post-NACT for pts with high-risk HER2-positive early breast cancer who did not achieve a pCR after standard NACT and anti-HER2 therapy.
December 10, 2025 at 10:09 PM
gbg.de
📣 Meet #GBG at #SABCS2025 – Highlights for December 10!

Another strong day for GBG at the San Antonio Breast Cancer Symposium with key data on #HER2+ early breast cancer, #TNBC immuno- #chemotherapy response #biology, and multiple high-impact external collaborations.
December 10, 2025 at 10:05 PM
gbg.de
🧬 #SABCS2025 | Impact of Checkpoint Inhibition on Fertility in Young Women with Early TNBC

Key Findings from the #NSABP B-59/GBG-96-GeparDouze Substudy presented by Mattea Reinisch

➡️ For more details and the full presentation, please visit the #GBG website:
www.gbg.de/news/detail/...

#GeparDouze
December 10, 2025 at 8:09 PM
gbg.de
At #SABCS2025, Brooke M. Felsheim presented a pooled analysis of three major randomized trials - #BrighTNess, #CALGB40603, and #GeparSixto—providing one of the most comprehensive evaluations to date of #carboplatin in early-stage triple-negative breast cancer (TNBC).
December 10, 2025 at 8:05 PM
gbg.de
📢 Key Findings from Our #SABCS2025 Presentation
Prognostic Markers in Residual TNBC After Neoadjuvant Chemotherapy – Pooled Analysis from Nine #GBG/AGO-B Trials Presented by Johannes Holtschmidt
➡️ For more details and the full presentation, please visit the GBG website: www.gbg.de/news/detail/...
December 10, 2025 at 8:03 PM
gbg.de
📣 Meet #GBG at #SABCS2025 – Highlights for December 9!

3 high-impact Rapid Fire Presentations featuring new analyses from leading #neoadjuvant and #immunotherapy trials.

All presentation materials will be made available after the conference here: www.gbg.de/news/detail/...
December 9, 2025 at 10:45 PM
gbg.de
📢 The #TAMENDOX study #GBG91 has been published in #CCR, presenting new evidence on optimizing #endocrine therapy in patients with impaired #tamoxifen metabolism.

Read full text here: aacrjournals.org/clincancerre...
Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
AbstractPurpose. :Tamoxifen undergoes bioactivation to its active metabolite (Z)-endoxifen, which blocks estrogen-dependent breast tumor growth at high potency. We tested the feasibility and safety of...
aacrjournals.org
December 2, 2025 at 9:31 PM
Reposted by GBG
goetheuni.bsky.social
„Highly Cited“ Goethe-Forscher*innen 2025 ⤵️
▪️ Prof. Dr. Florian Büttner
▪️ Prof. Dr. Ivan Đikić
▪️ Prof. Dr. Florian Greten @loewe-fci.bsky.social
▪️ Prof. Dr. Gerhard Hummer @mpibp.bsky.social
▪️ apl. Prof. Dr. Sibylle Loibl @gbg.de
▪️ Prof. Dr. Stefan Offermanns
▪️ Prof. Dr. Klement Tockner @sgn.one
November 14, 2025 at 11:58 AM
gbg.de
PinkOctober – Research Brings Hope: #INSEMA Study #GBG75

📖 Most recent results have been published in #NEJM: www.nejm.org/doi/full/10....

Exciting news: the latest INSEMA data will be presented as an Oral Presentation at the San Antonio Breast Cancer Symposium #SABCS2025 this December.
October 30, 2025 at 10:01 AM
gbg.de
#NeoRad study #GBG116: phase III trial investigating whether #preoperative radiotherapy can improve disease-free survival compared to #postoperative #radiotherapy after #neoadjuvant #chemotherapy in patients with high-risk early breast cancer.
👉 More information: www.gbg.de/en/trials/neorad
October 29, 2025 at 9:49 PM
gbg.de
#PinkOctober - #ASCENT-05: Phase III study investigates whether #Sacituzumab #Govitecan in combination with #Pembrolizumab can further improve outcomes compared to physician’s choice of standard therapy in pts with early TNBC who still have residual invasive disease after NACT and surgery
October 29, 2025 at 7:57 AM
gbg.de
Today at the #DGHO Annual Meeting 2025 #Cologne: #GBG presents exciting new research on combination therapy for #BRCA-mutated #breastcancer! Proud to share the #ELEMENT study #GBG114 — a randomized phase II trial exploring whether adding the oral #SERD #elacestrant to the #PARP inhibitor #olaparib.
October 27, 2025 at 4:56 PM
gbg.de
Published in #BCR this year introduces a powerfulprediction model for pathological complete response in #HER2-negative #breastcancer, developed using data from more than 1,100 pts: observational Hannover Breast Cancer Study and randomized #GeparSepto #GBG69 and #GeparOcto #GBG84 #clinicaltrials.
October 26, 2025 at 7:18 PM
gbg.de
In this #BreastCancerAwarenessMonth, we are excited to share that #GBG will have a strong scientific presence at the San Antonio Breast Cancer Symposium #SABCS2025 — one of the most important international meetings in breast cancer research. 💡
October 26, 2025 at 8:56 AM
gbg.de
#GeparPiPPa #GBG105 investigates #neoadjuvant #endocrine therapy in combination with #trastuzumab and #pertuzumab, with or without the #PI3K inhibitor #inavolisib, in patients with HER2-positive, HR-positive, PIK3CA-mutated primary breast cancer.
Learn more about the study www.gbg.de/en/trials/ge...
GeparPiPPa
Phase II trial comparing neoadjuvant endocrine therapy in combination with the PI3K-Inhibitor Inavolisib
www.gbg.de
October 24, 2025 at 3:38 PM
gbg.de
#BreastCancerAwarenessMonth2025: This October, as we raise awareness for #breastcancer and highlight the importance of long-term patient care, we invite all former study participants to take part in the #GBG071 #Registry

👉 Learn more and register here: www.gbg.de/en/trials/re...
October 23, 2025 at 2:48 PM
gbg.de
#Flamingo-01 #GBG111: a global phase III, randomized, placebo-controlled study investigating the GLSI-100 immunotherapy in HLA-A*02-positive and HER2/neu-positive breast cancer patients who remain at high risk of #recurrence after completing both #neoadjuvant and #adjuvant standard therapy.
October 22, 2025 at 8:12 PM
gbg.de
#PinkOctober: The study reveals that luminal breast tumors can dynamically change under #neoadjuvant #chemotherapy - with aggressive #Luminal B tumors often transitioning into a less aggressive Luminal A type.

Read full publication here: www.cell.com/cancer-cell/...
October 22, 2025 at 7:03 AM
gbg.de
#PinkOctober | #ESMO2025

#BMBC registry #GBG79 as poster presentation: The results highlight the importance of retesting #HER2 status in #metastatic sites and open the door to new, targeted treatment opportunities — even for patients previously classified as HER2-negative.
October 20, 2025 at 9:43 PM
gbg.de
#ESMO2025 #GBG presented long-term results from #GeparNuevo trial #GBG96 providing new insights into the role of immunotherapy in early #TNBC - survival benefit for #PD-L1 inhibitor was showed.
This is the only trial with benefit in combination with dose-dense chemotherapy without carboplatin!
October 20, 2025 at 10:42 AM